Pluripotency markers are differentially induced by MEK inhibition in thyroid and melanoma BRAFV600E cell lines

References

• Houben R, Becker J, Kappel A, Terheyden P, Bröcker E, Goetz R, Rapp U. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog 2004; 3:6; PMID:15046639; http://dx.doi.org/10.1186/1477-3163-3-6
   PubMedGoogle Scholar
• Tang K, Lee C. BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications. J Chin Med Assoc 2010; 73:113-28; PMID:20230995; http://dx.doi.org/10.1016/S1726-4901(10)70025-3
   PubMed Web of Science ®Google Scholar
• Sawyers C. Targeted cancer therapy. Nature 2004; 432:294-7; PMID:15549090; http://dx.doi.org/10.1038/nature03095
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-16; PMID:21639808; http://dx.doi.org/10.1056/NEJMoa1103782
   PubMed Web of Science ®Google Scholar
• Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010; 468:973-7; PMID:21107323; http://dx.doi.org/10.1038/nature09626
   PubMed Web of Science ®Google Scholar
• Montagut C, Sharma S, Shioda T, McDermott U, Ulman M, Ulkus L, Dias-Santagata D, Stubbs H, Lee D, Singh A, et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res 2008; 68:4853-61; PMID:18559533; http://dx.doi.org/10.1158/0008-5472.CAN-07-6787
   PubMed Web of Science ®Google Scholar
• Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011; 480:387-90; PMID:22113612; http://dx.doi.org/10.1038/nature10662
   PubMed Web of Science ®Google Scholar
• Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010; 468:968-72; PMID:21107320; http://dx.doi.org/10.1038/nature09627
   PubMed Web of Science ®Google Scholar
• Smalley KS, McArthur GA. The current state of targeted therapy in melanoma: this time it's personal. Semin Oncol 2012; 39:204-14; PMID:22484192; http://dx.doi.org/10.1053/j.seminoncol.2012.01.008
   PubMed Web of Science ®Google Scholar
• Solit D, Garraway L, Pratilas C, Sawai A, Getz G, Basso A, Ye Q, Lobo J, She Y, Osman I, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006; 439:358-62; PMID:16273091; http://dx.doi.org/10.1038/nature04304
   PubMed Web of Science ®Google Scholar
• Flaherty KT. BRAF inhibitors and melanoma. Cancer J 2011; 17:505-11; PMID:22157295; http://dx.doi.org/10.1097/PPO.0b013e31823e5357
   PubMed Web of Science ®Google Scholar
• Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010; 18:683-95; PMID:21156289; http://dx.doi.org/10.1016/j.ccr.2010.11.023
   PubMed Web of Science ®Google Scholar
• Gopal YN, Deng W, Woodman SE, Komurov K, Ram P, Smith PD, Davies MA. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res 2010; 70:8736-47; PMID:20959481; http://dx.doi.org/10.1158/0008-5472.CAN-10-0902
   PubMed Web of Science ®Google Scholar
• Haass NK, Sproesser K, Nguyen TK, Contractor R, Medina CA, Nathanson KL, Herlyn M, Smalley KS. The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res 2008; 14:230-9; PMID:18172275; http://dx.doi.org/10.1158/1078-0432.CCR-07-1440
   PubMed Web of Science ®Google Scholar
• Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, et al. Combined BRAF and MEK Inhibition vs. BRAF Inhibition Alone in Melanoma. N Eng J Med 2014; 371:1877-88; PMID:25265492; http://dx.doi.org/10.1056/NEJMoa1406037
   PubMed Web of Science ®Google Scholar
• Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, et al. Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma. N Engl J Med 2014; 371:1867-76; PMID:25265494; http://dx.doi.org/10.1056/NEJMoa1408868
   PubMed Web of Science ®Google Scholar
• Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: approaches and considerations. Nat Rev Genet 2012; 13:358-69; PMID:22510765; http://dx.doi.org/10.1038/nrg3198
   PubMed Web of Science ®Google Scholar
• Olszewski WL, Moscicka M, Zolich D, Machowski Z. Human keratinocyte stem cells survive for months in sodium chloride and can be successfully transplanted. Transplantation Proc 2005; 37:525-6; PMID:15808698; http://dx.doi.org/10.1016/j.transproceed.2004.12.174
   PubMed Web of Science ®Google Scholar
• Smyth P, Finn S, Cahill S, O'Regan E, Flavin R, O'Leary JJ, Sheils O. ret/PTC and BRAF act as distinct molecular, time-dependant triggers in a sporadic Irish cohort of papillary thyroid carcinoma. Int J Surg Pathol 2005; 13:1-8; PMID:15735849; http://dx.doi.org/10.1177/106689690501300101
   PubMed Web of Science ®Google Scholar
• Freeley M, O'Dowd F, Paul T, Kashanin D, Davies A, Kelleher D, Long A. L-plastin regulates polarization and migration in chemokine-stimulated human T lymphocytes. J Immunol 2012; 188:6357-70; PMID:22581862; http://dx.doi.org/10.4049/jimmunol.1103242
   PubMed Web of Science ®Google Scholar
• Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol 2010; 11:R106; http://dx.doi.org/10.1186/gb-2010-11-10-r106
   PubMed Web of Science ®Google Scholar
• Li S, Wang H, Qi Y, Tu J, Bai Y, Tian T, Huang N, Wang Y, Xiong F, Lu Z, et al. Assessment of nanomaterial cytotoxicity with SOLiD sequencing-based microRNA expression profiling. Biomaterials 2011; 32:9021-30; PMID:21889204; http://dx.doi.org/10.1016/j.biomaterials.2011.08.033
   PubMed Web of Science ®Google Scholar
• Dweep H, Sticht C, Pandey P, Gretz N. miRWalk–database: prediction of possible miRNA binding sites by “walking” the genes of three genomes. J Biomed Inform 2011; 44:839-47; PMID:21605702; http://dx.doi.org/10.1016/j.jbi.2011.05.002
   PubMed Web of Science ®Google Scholar
• Beissbarth T, Speed TP. GOstat: find statistically overrepresented Gene Ontologies within a group of genes. Bioinformatics 2004; 20:1464-5; PMID:14962934; http://dx.doi.org/10.1093/bioinformatics/bth088
   PubMed Web of Science ®Google Scholar
• Xing J, Liu R, Xing M, Trink B. The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204). Biochem Biophys Res Commun 2011; 404:958-62; PMID:21185263; http://dx.doi.org/10.1016/j.bbrc.2010.12.088
   PubMed Web of Science ®Google Scholar
• Henderson YC, Chen Y, Frederick MJ, Lai SY, Clayman GL. MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo. Mol Cancer Ther 2010; 9:1968-76; PMID:20587665; http://dx.doi.org/10.1158/1535-7163.MCT-10-0062
   PubMed Web of Science ®Google Scholar
• Leboeuf R, Baumgartner JE, Benezra M, Malaguarnera R, Solit D, Pratilas CA, Rosen N, Knauf JA, Fagin JA. BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. J Clin Endocrinol Metab 2008; 93:2194-201; PMID:18381570; http://dx.doi.org/10.1210/jc.2007-2825
   PubMed Web of Science ®Google Scholar
• Subramanyam D, Lamouille S, Judson RL, Liu JY, Bucay N, Derynck R, Blelloch R. Multiple targets of miR-302 and miR-372 promote reprogramming of human fibroblasts to induced pluripotent stem cells. Nat Biotechnol 2011; 29:443-8; PMID:21490602; http://dx.doi.org/10.1038/nbt.1862
   PubMed Web of Science ®Google Scholar
• Ren J, Jin P, Wang E, Marincola FM, Stroncek DF. MicroRNA and gene expression patterns in the differentiation of human embryonic stem cells. J Transl Med 2009; 7:20; PMID:19309508; http://dx.doi.org/10.1186/1479-5876-7-20
   PubMed Web of Science ®Google Scholar
• Mazda M, Nishi K, Naito Y, Ui-Tei K. E-cadherin is transcriptionally activated via suppression of ZEB1 transcriptional repressor by small RNA-mediated gene silencing. PLoS One 2011; 6:e28688; PMID:22205962; http://dx.doi.org/10.1371/journal.pone.0028688
   PubMed Web of Science ®Google Scholar
• Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012; 9:671-5; PMID:22930834; http://dx.doi.org/10.1038/nmeth.2089
   PubMed Web of Science ®Google Scholar
• Wienholds E, Plasterk RH. MicroRNA function in animal development. FEBS Lett 2005; 579:5911-22; PMID:16111679; http://dx.doi.org/10.1016/j.febslet.2005.07.070
   PubMed Web of Science ®Google Scholar
• Alvarez-Garcia I, Miska EA. MicroRNA functions in animal development and human disease. Development 2005; 132:4653-62; PMID:16224045; http://dx.doi.org/10.1242/dev.02073
   PubMed Web of Science ®Google Scholar
• Morin RD, O'Connor MD, Griffith M, Kuchenbauer F, Delaney A, Prabhu AL, Zhao Y, McDonald H, Zeng T, Hirst M, et al. Application of massively parallel sequencing to microRNA profiling and discovery in human embryonic stem cells. Genome Res 2008; 18:610-21; PMID:18285502; http://dx.doi.org/10.1101/gr.7179508
   PubMed Web of Science ®Google Scholar
• Lakshmipathy U, Love B, Goff LA, Jörnsten R, Graichen R, Hart RP, Chesnut JD. MicroRNA expression pattern of undifferentiated and differentiated human embryonic stem cells. Stem Cells Dev 2007; 16:1003-16; PMID:18004940; http://dx.doi.org/10.1089/scd.2007.0026
   PubMed Web of Science ®Google Scholar
• Suh MR, Lee Y, Kim JY, Kim SK, Moon SH, Lee JY, Cha KY, Chung HM, Yoon HS, Moon SY, et al. Human embryonic stem cells express a unique set of microRNAs. Dev Biol 2004; 270:488-98; PMID:15183728; http://dx.doi.org/10.1016/j.ydbio.2004.02.019
   PubMed Web of Science ®Google Scholar
• Chen C, Ridzon D, Lee CT, Blake J, Sun Y, Strauss WM. Defining embryonic stem cell identity using differentiation-related microRNAs and their potential targets. Mamm Genome 2007; 18:316-27; PMID:17610011; http://dx.doi.org/10.1007/s00335-007-9032-6
   PubMed Web of Science ®Google Scholar
• Tang F, Hajkova P, Barton SC, Lao K, Surani MA. MicroRNA expression profiling of single whole embryonic stem cells. Nucleic Acids Res 2006; 34:e9; PMID:16434699; http://dx.doi.org/10.1093/nar/gnj009
   PubMed Web of Science ®Google Scholar
• Houbaviy HB, Murray MF, Sharp PA. Embryonic stem cell-specific MicroRNAs. Dev Cell 2003; 5:351-8; PMID:12919684; http://dx.doi.org/10.1016/S1534-5807(03)00227-2
   PubMed Web of Science ®Google Scholar
• Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006; 5:67; PMID:17140455; http://dx.doi.org/10.1186/1476-4598-5-67
   PubMed Web of Science ®Google Scholar
• Li S, Li D. Stem cell and kinase activity-independent pathway in resistance of leukaemia to BCR-ABL kinase inhibitors. J Cell Mol Med 2007; 11:1251-62; PMID:18205699; http://dx.doi.org/10.1111/j.1582-4934.2007.00108.x
   PubMed Web of Science ®Google Scholar
• Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5:275-84; PMID:15803154; http://dx.doi.org/10.1038/nrc1590
   PubMed Web of Science ®Google Scholar
• Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414:105-11; PMID:11689955; http://dx.doi.org/10.1038/35102167
   PubMed Web of Science ®Google Scholar
• Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C, Lander ES. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 2011; 146:633-44; PMID:21854987; http://dx.doi.org/10.1016/j.cell.2011.07.026
   PubMed Web of Science ®Google Scholar
• Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO, Brooks M, Reinhardt F, Su Y, Polyak K, et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci U S A 2011; 108:7950-5; PMID:21498687; http://dx.doi.org/10.1073/pnas.1102454108
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367:107-14; PMID:22663011; http://dx.doi.org/10.1056/NEJMoa1203421
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Bastholt L, Robert C, Sosman J, Larkin J, Hersey P, Middleton M, Cantarini M, Zazulina V, Kemsley K, et al. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res 2012; 18:555-67; PMID:22048237; http://dx.doi.org/10.1158/1078-0432.CCR-11-1491
   PubMed Web of Science ®Google Scholar
• Smalley KS, Flaherty KT. Integrating BRAF/MEK inhibitors into combination therapy for melanoma. Br J Cancer 2009; 100:431-5; PMID:19156138; http://dx.doi.org/10.1038/sj.bjc.6604891
   PubMed Web of Science ®Google Scholar
• Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, Hanson LJ, Gore L, Chow L, Leong S, et al. Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers. J Clin Oncol 2008; 26:2139-46; PMID:18390968; http://dx.doi.org/10.1200/JCO.2007.14.4956
   PubMed Web of Science ®Google Scholar
• Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009; 9:28-39; PMID:19104514; http://dx.doi.org/10.1038/nrc2559
   PubMed Web of Science ®Google Scholar
• English JM, Cobb MH. Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci 2002; 23:40-5; PMID:11804650; http://dx.doi.org/10.1016/S0165-6147(00)01865-4
   PubMed Web of Science ®Google Scholar
• Ashworth A, Lord CJ, Reis-Filho JS. Genetic interactions in cancer progression and treatment. Cell 2011; 145:30-8; PMID:21458666; http://dx.doi.org/10.1016/j.cell.2011.03.020
   PubMed Web of Science ®Google Scholar
• Turner NC, Reis-Filho JS. Genetic heterogeneity and cancer drug resistance. Lancet Oncol 2012; 13:e178-85; PMID:22469128; http://dx.doi.org/10.1016/S1470-2045(11)70335-7
   PubMed Web of Science ®Google Scholar
• Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010; 467:596-9; PMID:20823850; http://dx.doi.org/10.1038/nature09454
   PubMed Web of Science ®Google Scholar
• Girotti Maria R, Lopes F, Preece N, Niculescu-Duvaz D, Zambon A, Davies L, Whittaker S, Saturno G, Viros A, Pedersen M, et al. Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma. Cancer Cell 2015; 27:85-96; PMID:25500121; http://dx.doi.org/10.1016/j.ccell.2014.11.006
   PubMed Web of Science ®Google Scholar
• Aplin AE, Stewart SA, Assoian RK, Juliano RL. Integrin-mediated adhesion regulates ERK nuclear translocation and phosphorylation of Elk-1. J Cell Biol 2001; 153:273-82; PMID:11309409; http://dx.doi.org/10.1083/jcb.153.2.273
   PubMed Web of Science ®Google Scholar
• Bharadwaj S, Vasanth G, Masuelli L, Thanawala R, Prasad G. Inhibition of Nuclear Accumulation of Phosphorylated ERK by Tropomyosin-1–Mediated Cytoskeletal Reorganization. J Cancer Mol 2008; 4:139-44
   Google Scholar
• Adachi M, Fukuda M, Nishida E. Nuclear export of MAP kinase (ERK) involves a MAP kinase kinase (MEK)-dependent active transport mechanism. J Cell Biol 2000; 148:849-56; PMID:10704436; http://dx.doi.org/10.1083/jcb.148.5.849
   PubMed Web of Science ®Google Scholar
• Wortzel I, Seger R. The ERK Cascade: Distinct Functions within Various Subcellular Organelles. Genes Cancer 2011; 2:195-209; PMID:21779493; http://dx.doi.org/10.1177/1947601911407328
   PubMedGoogle Scholar
• White CD, Brown MD, Sacks DB. IQGAPs in cancer: a family of scaffold proteins underlying tumorigenesis. FEBS Lett 2009; 583:1817-24; PMID:19433088; http://dx.doi.org/10.1016/j.febslet.2009.05.007
   PubMed Web of Science ®Google Scholar
• Ren JG, Li Z, Sacks DB. IQGAP1 modulates activation of B-Raf. Proc Natl Acad Sci U S A 2007; 104:10465-9; PMID:17563371; http://dx.doi.org/10.1073/pnas.0611308104
   PubMed Web of Science ®Google Scholar
• Niu J, Mo Q, Wang H, Li M, Cui J, Li Z. Invasion inhibition by a MEK inhibitor correlates with the actin-based cytoskeleton in lung cancer A549 cells. Biochem Biophys Res Commun 2012; 422:80-4; PMID:22560902; http://dx.doi.org/10.1016/j.bbrc.2012.04.109
   PubMed Web of Science ®Google Scholar
• Pierce GB. Neoplastic stem cells. Adv Pathobiol 1977; 6:141-52; PMID:899956
   PubMedGoogle Scholar
• Salmon SE. Applications of the human tumor stem cell assay to new drug evaluation and screening. Prog Clin Biol Res 1980; 48:291-312; PMID:7193873
   PubMedGoogle Scholar
• Kumar SM, Liu S, Lu H, Zhang H, Zhang PJ, Gimotty PA, Guerra M, Guo W, Xu X. Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation. Oncogene 2012; 31(47):4898-911
   PubMed Web of Science ®Google Scholar
• Daley GQ. Common themes of dedifferentiation in somatic cell reprogramming and cancer. Cold Spring Harb Symp Quant Biol 2008; 73:171-4; PMID:19150965; http://dx.doi.org/10.1101/sqb.2008.73.041
   PubMedGoogle Scholar
• Kim JB, Greber B, Araúzo-Bravo MJ, Meyer J, Park KI, Zaehres H, Schöler HR. Direct reprogramming of human neural stem cells by OCT4. Nature 2009; 461:649-3; PMID:19718018; http://dx.doi.org/10.1038/nature08436
   PubMed Web of Science ®Google Scholar
• Lin SL, Chang DC, Ying SY, Leu D, Wu DT. MicroRNA miR-302 inhibits the tumorigenecity of human pluripotent stem cells by coordinate suppression of the CDK2 and CDK4/6 cell cycle pathways. Cancer Res 2010; 70:9473-82; PMID:21062975; http://dx.doi.org/10.1158/0008-5472.CAN-10-2746
   PubMed Web of Science ®Google Scholar
• Lin SL, Chang DC, Lin CH, Ying SY, Leu D, Wu DT. Regulation of somatic cell reprogramming through inducible mir-302 expression. Nucleic Acids Res 2011; 39:1054-65; PMID:20870751; http://dx.doi.org/10.1093/nar/gkq850
   PubMed Web of Science ®Google Scholar
• Fareh M, Turchi L, Virolle V, Debruyne D, Almairac F, de-la-Forest Divonne S, Paquis P, Preynat-Seauve O, Krause KH, Chneiweiss H, et al. The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network. Cell Death Differ 2012; 19:232-44; http://dx.doi.org/10.1038/cdd.2011.89
   PubMed Web of Science ®Google Scholar
• Bourguignon LY, Wong G, Earle C, Chen L. Hyaluronan-CD44v3 interaction with Oct4/Sox2/Nanog promotes miR-302 expression leading to self-renewal, clonal formation and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma. J Biol Chem 2012; 287(39):32800-24; PMID:22847005; http://dx.doi.org/10.1074/jbc.M111.308528
   PubMed Web of Science ®Google Scholar
• Lipchina I, Elkabetz Y, Hafner M, Sheridan R, Mihailovic A, Tuschl T, Sander C, Studer L, Betel D. Genome-wide identification of microRNA targets in human ES cells reveals a role for miR-302 in modulating BMP response. Genes Dev 2011; 25:2173-86; PMID:22012620; http://dx.doi.org/10.1101/gad.17221311
   PubMed Web of Science ®Google Scholar
• Judson RL, Babiarz JE, Venere M, Blelloch R. Embryonic stem cell-specific microRNAs promote induced pluripotency. Nat Biotechnol 2009; 27:459-61; PMID:19363475; http://dx.doi.org/10.1038/nbt.1535
   PubMed Web of Science ®Google Scholar
• Theunissen TW, van Oosten AL, Castelo-Branco G, Hall J, Smith A, Silva JC. Nanog overcomes reprogramming barriers and induces pluripotency in minimal conditions. Curr Biol 2011; 21:65-71; PMID:21194951; http://dx.doi.org/10.1016/j.cub.2010.11.074
   PubMed Web of Science ®Google Scholar
• Ding VM, Ling L, Natarajan S, Yap MG, Cool SM, Choo AB. FGF-2 modulates Wnt signaling in undifferentiated hESC and iPS cells through activated PI3-K/GSK3beta signaling. J Cell Physiol 2010; 225:417-28; PMID:20506199; http://dx.doi.org/10.1002/jcp.22214
   PubMed Web of Science ®Google Scholar
• Armstrong L, Hughes O, Yung S, Hyslop L, Stewart R, Wappler I, Peters H, Walter T, Stojkovic P, Evans J, et al. The role of PI3K/AKT, MAPK/ERK and NFkappabeta signalling in the maintenance of human embryonic stem cell pluripotency and viability highlighted by transcriptional profiling and functional analysis. Hum Mol Genet 2006; 15:1894-913; http://dx.doi.org/10.1093/hmg/ddl112
   PubMed Web of Science ®Google Scholar